Concord Biotech approves 1:1 bonus shares issue and share capital increase
Concord Biotech · Pharmaceuticals & Biotechnology
What the filing says
- Board approved 1:1 bonus issue of equity shares worth ₹10.46 crore by capitalizing share premium
- Authorized share capital increased from ₹11 crore to ₹22 crore, adding 11 crore equity shares
- Bonus shares to be credited within 2 months of approval, by November 22, 2026
Original filing
Board Meeting Outcome for The Board Of Director At Its Meeting Held Today I.E. Wednesday, September 23, 2026, Has Inter-Alia Considered And Approved Issuance Of Bonus Shares & Increase In The Authorised Share Capital Of The Company.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Concord Biotech
- Dividend / buyback / bonusConcord Biotech announces Board meeting on Sept 23, 2026, to consider bonus shares
Other dividend / buyback / bonus filings this fortnight
- Dividend / buyback / bonusPashupati Cotspin LtdPashupati Cotspin Limited schedules 6th Board Meeting on October 3, 2026
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India Ltd announces subsidiary in China and share buyback
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India approves buyback of shares and China subsidiary
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India approves buyback and China subsidiary incorporation
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India Ltd approves buyback and to incorporate China subsidiary
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India Ltd discloses promoters will not participate in buyback
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.